A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00532779 |
|
Recruitment Status :
Completed
First Posted : September 20, 2007
Results First Posted : November 21, 2014
Last Update Posted : November 21, 2014
|
Sponsor:
Orexigen Therapeutics, Inc
Information provided by (Responsible Party):
Orexigen Therapeutics, Inc
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to determine whether 2 doses of the combination of naltrexone SR and bupropion SR are safe and effective in the treatment of obesity.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Obesity Overweight | Drug: Naltrexone SR 16 mg/Bupropion SR 360 mg /day Drug: Naltrexone SR 32 mg/Bupropion SR 360 mg /day Drug: Placebo Behavioral: Ancillary therapy | Phase 3 |
Two Phase II clinical trials demonstrated that a combination of bupropion SR and naltrexone is associated with greater weight loss than bupropion SR alone, naltrexone alone, or placebo in subjects with uncomplicated obesity. The current study investigated the safety and efficacy of 2 doses of the combination of naltrexone SR and bupropion SR compared to placebo in obese subjects with uncomplicated obesity and in those with overweight/obesity and hypertension and/or dyslipidemia.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 1742 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Two Doses of Naltrexone Sustained Release (SR)/Bupropion Sustained Release (SR) and Placebo in Obese Subjects |
| Study Start Date : | October 2007 |
| Actual Primary Completion Date : | May 2009 |
| Actual Study Completion Date : | May 2009 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Experimental: NB16
Naltrexone SR 16 mg/Bupropion SR 360 mg /day with ancillary therapy
|
Drug: Naltrexone SR 16 mg/Bupropion SR 360 mg /day
Other Name: NB16 Behavioral: Ancillary therapy Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling |
|
Experimental: NB32
Naltrexone SR 32 mg/Bupropion SR 360 mg /day with ancillary therapy
|
Drug: Naltrexone SR 32 mg/Bupropion SR 360 mg /day
Other Name: NB32 Behavioral: Ancillary therapy Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling |
|
Placebo Comparator: Placebo
Placebo with ancillary therapy
|
Drug: Placebo Behavioral: Ancillary therapy Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling |
Primary Outcome Measures :
- Co-primary: Body Weight- Mean Percent Change [ Time Frame: Baseline, 56 weeks ]
- Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease [ Time Frame: Baseline, 56 weeks ]
Secondary Outcome Measures :
- Body Weight- Proportion of Subjects With ≥10% Decrease [ Time Frame: Baseline, 56 weeks ]
- Change in Waist Circumference [ Time Frame: Baseline, 56 weeks ]
- Change in Fasting HDL Cholesterol Levels [ Time Frame: Baseline, 56 weeks ]
- Change in Fasting Triglycerides Levels, Using Log-transformed Data [ Time Frame: Baseline, 56 weeks ]
- Change in IWQOL-Lite Total Scores [ Time Frame: Baseline, 56 weeks ]IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment
- Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data [ Time Frame: Baseline, 56 weeks ]
- Change in Fasting Insulin Levels, Using Log-transformed Data [ Time Frame: Baseline, 56 weeks ]
- Change in Fasting Blood Glucose Levels [ Time Frame: Baseline, 56 weeks ]
- Change in HOMA-IR Levels, Using Log-transformed Data [ Time Frame: Baseline, 56 weeks ]HOMA-IR= Homeostasis Model Assessment-Insulin Resistance
- Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire [ Time Frame: Baseline, 56 weeks ]Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult
- Change in Fasting LDL Cholesterol Levels [ Time Frame: Baseline, 56 weeks ]
- Change in Systolic Blood Pressure [ Time Frame: Baseline, 56 weeks ]
- Change in Diastolic Blood Pressure [ Time Frame: Baseline, 56 weeks ]
- Change in IDS-SR Total Scores [ Time Frame: Baseline, 56 weeks ]IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression.
- Change in Food Craving Inventory Sweets Subscale Score [ Time Frame: Baseline, 56 weeks ]The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).
- Change in Food Craving Inventory Carbohydrates Subscale Score [ Time Frame: Baseline, 56 weeks ]The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Female and male subjects, 18 to 65 years of age;
- Have BMI ≥30 and ≤45kg/m² for subjects with uncomplicated obesity, and BMI of ≥27 and ≤45kg/m² for subjects with obesity and controlled hypertension and/or dyslipidemia;
- Normotensive (systolic ≤140 mm Hg; diastolic ≤90 mm Hg). Anti-hypertensive medications are allowed with the exception of alpha-adrenergic blockers and clonidine; medical regimen must be stable for at least 6 weeks prior to randomization;
- Medications for treatment of dyslipidemia are allowed as long as medical regimen has been stable for at least 6 weeks prior to randomization;
- Free of opioid medication for 7 days prior to randomization;
- No clinically significant abnormality of serum albumin, blood urea nitrogen, creatinine, bilirubin, sodium, potassium, chloride, calcium or phosphorus;
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within 2.5 x upper limit of normal range (ULN);
- No clinically significant abnormality of hematocrit, white blood cell (WBC) count, white cell differential, or platelets;
- Fasting glucose < 126 mg/dL on no hypoglycemic agents, fasting triglycerides <400 mg/dL;
- No clinically significant abnormality on urinalysis;
- TSH within normal limits or normal T3, if TSH is below normal limits;
- Negative serum pregnancy test in women of child-bearing potential;
- Negative urine drug screen;
- IDS-SR scores < 2 on items 5 (sadness), 6 (irritability), 7 (anxiety/tension) and 18 (suicidality), and IDS-SR total score < 30;
- Women of child bearing potential had to be non-lactating and agree to use effective contraception throughout the study period and 30 days after discontinuation of study drug;
- Able to comply with all required study procedures and schedule;
- Able to speak and read English;
- Willing and able to give written informed consent.
Exclusion Criteria:
- Obesity of known endocrine origin (e.g., untreated hypothyroidism, Cushing's syndrome, established Polycystic Ovary Syndrome);
- Serious medical conditions (including but not limited to ongoing renal or hepatic insufficiency, Class III or IV congestive heart failure; myocardial infarction, history of angina pectoris, claudication, or acute limb ischemia within the previous 6 months; lifetime history of stroke);
- History of malignancy within the previous 5 years with exception of non-melanoma skin cancer or surgically cured cervical cancer;
- A lifetime history of serious psychiatric illness, including lifetime history of bipolar disorder, schizophrenia or other psychosis, bulimia, or anorexia nervosa;
- Current serious psychiatric illness including severe personality disorder, (e.g. borderline or antisocial), current severe major depressive disorder, recent (previous 6 months) suicide attempt, current active suicidal ideation, or recent hospitalization due to psychiatric illness;
- A response to bipolar disorder questions indicating the presence of bipolar disorder;
- In need of medications for the treatment of a psychiatric disorder (with the exception of short-term insomnia) within the previous 6 months prior to randomization;
- History of drug or alcohol abuse or dependence (with the exception of nicotine dependence) within 1 year prior to study initiation;
- Type 1 or Type 2 diabetes mellitus;
- Screening ECG with a corrected QT interval by the method of Bazett (QTcB) >450 msec (men) and > 470 millisecond (msec) (women) or the presence of any clinically significant cardiac abnormalities, including but not limited to patterns consistent with myocardial ischemia, electrolyte abnormalities, or atrial or ventricular dysrhythmia or significant conduction abnormalities;
- Excluded concomitant medications: any psychotropic agents (including antipsychotic, antidepressant, anxiolytic, mood stabilizer, anticonvulsant agents or agents for the treatment of Attention Deficit Disorder) with the exception of low dose benzodiazepine or hypnotic agents for the treatment of insomnia (up to 2 mg lorazepam/day or equivalent dose of a benzodiazepine or hypnotic agent); any anorectic or weight loss agents; any over-the-counter dietary supplements or herbs with psychoactive, appetite or weight effects; alpha-adrenergic blockers; dopamine agonists; clonidine; coumadin; theophylline; cimetidine; oral corticosteroids; cholestyramine, cholestypol, Depo Provera®; smoking cessation agents; use of opioid or opioid-like medications, including analgesics and antitussives;
- History of surgical or device (e.g., gastric banding) intervention for obesity;
- History of seizures of any etiology, or of predisposition to seizures (e.g., history of cerebrovascular accident, head trauma with ≥5 minutes loss of consciousness, concussion symptoms lasting ≥15 minutes, brain surgery, skull fracture, subdural hematoma, or febrile seizures);
- History of treatment with bupropion or naltrexone within the preceding 12 months;
- History of hypersensitivity or intolerance to bupropion or naltrexone;
- Initiation or discontinuation of tobacco products including inhaled tobacco (such as cigarettes, cigars, pipes, etc), chewing tobacco or snuff in the 3 months prior to randomization or planned during study participation. Use of nicotine replacement products (nicotine gum, patch) during study participation was not allowed;
- Use of drugs, herbs, or dietary supplements believed to significantly affect body weight or participation in a weight loss management program within one month prior to randomization;
- Loss or gain of more than 4.0 kilograms within 3 months prior to randomization;
- Pregnant or breast-feeding women or planning to become pregnant during the study period or within 30 days of discontinuing study drug;
- Planned surgical procedure that can impact the conduct of the study;
- Use of investigational drug, device or procedure within the previous 30 days;
- Participation in any previous clinical trial sponsored by Orexigen Therapeutics;
- Any condition which in the opinion of the investigator makes the subject unsuitable for inclusion in the study;
- Investigators, study personnel, sponsor representatives and their immediate families.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00532779
Locations
Show 34 study locations
Sponsors and Collaborators
Orexigen Therapeutics, Inc
Publications of Results:
| Responsible Party: | Orexigen Therapeutics, Inc |
| ClinicalTrials.gov Identifier: | NCT00532779 |
| Other Study ID Numbers: |
NB-301 COR-I ( Other Identifier: Orexigen Therapeutics, Inc. ) |
| First Posted: | September 20, 2007 Key Record Dates |
| Results First Posted: | November 21, 2014 |
| Last Update Posted: | November 21, 2014 |
| Last Verified: | November 2014 |
Keywords provided by Orexigen Therapeutics, Inc:
|
Bupropion administration and dosage Naltrexone administration and dosage Obesity Antiobesity agents Antiobesity drugs Overweight drug therapy |
Obese drug therapy Weight loss drug effects Double blind method Combination drug therapy Delayed action preparations |
Additional relevant MeSH terms:
|
Naltrexone Bupropion Overweight Overnutrition Nutrition Disorders Body Weight Alcohol Deterrents Narcotic Antagonists Physiological Effects of Drugs Sensory System Agents Peripheral Nervous System Agents Antidepressive Agents, Second-Generation |
Antidepressive Agents Psychotropic Drugs Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Dopamine Agents Neurotransmitter Agents Cytochrome P-450 CYP2D6 Inhibitors Cytochrome P-450 Enzyme Inhibitors Enzyme Inhibitors |